Medtronic (NYSE:MDT) Issues Quarterly Earnings Results

Medtronic (NYSE:MDT) posted its quarterly earnings results on Wednesday. The medical technology company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.01, FiscalAI reports. The business had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.61 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.

Medtronic Stock Performance

Shares of MDT stock opened at $73.72 on Wednesday. The company has a market capitalization of $94.65 billion, a P/E ratio of 20.54, a P/E/G ratio of 1.76 and a beta of 0.58. The business’s 50 day moving average is $82.11 and its two-hundred day moving average is $92.49. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic has a 12-month low of $73.31 and a 12-month high of $106.33.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a dividend of $0.71 per share. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.9%. Medtronic’s dividend payout ratio is currently 79.11%.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic beat fiscal Q4 estimates, with stronger-than-expected revenue and profit helping support the stock. Medtronic beats quarterly estimates on robust demand for heart devices
• Positive Sentiment: The company said fiscal 2026 revenue grew 8.4% and highlighted its strongest annual top-line growth in 10 years, which signals improving execution and demand across the portfolio. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
• Positive Sentiment: Cardiac Ablation Solutions revenue jumped 78% globally, including 124% growth in the U.S., reflecting strong physician adoption of Affera technologies. Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera technologies broadens
• Positive Sentiment: Medtronic advanced its Hugo robotic surgery platform with new FDA filings and clearances, expanding the system’s potential use in general and gynecologic procedures and supporting long-term growth in surgical robotics. Medtronic submits 510(k) filings to expand Hugo robotic-assisted surgery system into general and gynecologic specialties in the United States
• Neutral Sentiment: Management also raised the quarterly dividend to $0.72 per share and maintained a strong cash-flow profile, which is supportive but not the main near-term driver of the stock. Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
• Neutral Sentiment: Analysts had expected solid results ahead of the report, so some of the recent move may reflect positioning into earnings rather than a new surprise. Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
• Negative Sentiment: Despite the beat, investors appear to be looking past a softer outlook, suggesting the market still has concerns about the pace of future growth. Medtronic Stock Rises on Earnings. Wall Street Looks Past a Soft Outlook.

Analysts Set New Price Targets

MDT has been the topic of a number of recent research reports. Robert W. Baird upped their target price on Medtronic from $92.00 to $93.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Piper Sandler lowered their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 1st. Evercore set a $106.00 target price on Medtronic and gave the stock an “outperform” rating in a research note on Thursday, April 9th. Needham & Company LLC restated a “buy” rating and issued a $120.00 target price on shares of Medtronic in a research note on Thursday, March 26th. Finally, Mizuho lowered their target price on Medtronic from $125.00 to $120.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and a consensus target price of $106.45.

Hedge Funds Weigh In On Medtronic

A number of hedge funds have recently bought and sold shares of MDT. Wellington Management Group LLP boosted its position in Medtronic by 35.3% during the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after purchasing an additional 2,658,981 shares in the last quarter. AQR Capital Management LLC boosted its position in Medtronic by 68.3% during the third quarter. AQR Capital Management LLC now owns 3,329,414 shares of the medical technology company’s stock worth $314,397,000 after purchasing an additional 1,350,888 shares in the last quarter. Lazard Asset Management LLC boosted its position in Medtronic by 19.0% during the third quarter. Lazard Asset Management LLC now owns 6,001,342 shares of the medical technology company’s stock worth $571,502,000 after purchasing an additional 957,149 shares in the last quarter. Schroder Investment Management Group boosted its position in Medtronic by 12.5% during the fourth quarter. Schroder Investment Management Group now owns 8,468,982 shares of the medical technology company’s stock worth $813,530,000 after purchasing an additional 939,133 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in Medtronic by 62.6% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,430,723 shares of the medical technology company’s stock worth $231,502,000 after purchasing an additional 935,941 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).